Einzeltreffer — DigiBib

Antibody features vary with tuberculosis (TB) disease state. Whether clinical variables, such as age or sex, influence associations between Mycobacterium tuberculosis-specific antibody responses and disease state is not well explored. Here we profiled Mycobacterium tuberculosis-specific antibody responses in 140 TB-exposed South African individuals from the Adolescent Cohort Study. We identified distinct response features in individuals progressing to active TB from non-progressing, matched controls. A multivariate antibody score differentially associated with progression (SeroScore) identified progressors up to 2 years before TB diagnosis, earlier than that achieved with the RISK6 transcriptional signature of progression. We validated these antibody response features in the Grand Challenges 6-74 cohort. Both the SeroScore and RISK6 correlated better with risk of TB progression in adolescents compared with adults, and in males compared with females. This suggests that age and sex are important, underappreciated modifiers of antibody responses associated with TB progression.

Titel:	Age and sex influence antibody profiles associated with tuberculosis progression.
Autor/in / Beteiligte Person:	Davies, LRL ; Wang, C ; Steigler, P ; Bowman, KA ; Fischinger, S ; Hatherill, M ; Fisher, M ; Mbandi, SK ; Rodo, M ; Ottenhoff, THM ; Dockrell, HM ; Sutherland, JS ; Mayanja-Kizza, H ; Boom, WH ; Walzl, G ; Kaufmann, SHE ; Nemes, E ; Scriba, TJ ; Lauffenburger, D ; Alter, G ; Fortune, SM
Link:	View record at Springer (Volltext)
Zeitschrift:	Nature microbiology, Jg. 9 (2024-06-01), Heft 6, S. 1513-1525
Veröffentlichung:	[London] : Nature Publishing Group, [2016]-, 2024
Medientyp:	academicJournal
ISSN:	2058-5276 (electronic)
DOI:	10.1038/s41564-024-01678-x
Schlagwort:	Humans Male Female Adolescent Sex Factors Adult Age Factors South Africa epidemiology Young Adult Cohort Studies Antibody Formation immunology Mycobacterium tuberculosis immunology Antibodies, Bacterial blood Antibodies, Bacterial immunology Disease Progression Tuberculosis immunology Tuberculosis microbiology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Nat Microbiol] 2024 Jun; Vol. 9 (6), pp. 1513-1525. <i>Date of Electronic Publication: </i>2024 Apr 24. MeSH Terms: Mycobacterium tuberculosis* / immunology ; Antibodies, Bacterial* / blood ; Antibodies, Bacterial* / immunology ; Disease Progression* ; Tuberculosis* / immunology ; Tuberculosis* / microbiology ; Humans ; Male ; Female ; Adolescent ; Sex Factors ; Adult ; Age Factors ; South Africa / epidemiology ; Young Adult ; Cohort Studies ; Antibody Formation / immunology References: J Infect Dis. 2020 Nov 13;222(12):2093-2102. (PMID: 32060529) ; JAMA Netw Open. 2018 Oct 5;1(6):e183779. (PMID: 30646264) ; Am J Epidemiol. 1974 Feb;99(2):131-8. (PMID: 4810628) ; Nat Med. 2023 Jan;29(1):258-269. (PMID: 36604540) ; PLoS Med. 2019 Apr 16;16(4):e1002781. (PMID: 30990820) ; Trends Immunol. 2017 May;38(5):358-372. (PMID: 28385520) ; PLoS Pathog. 2017 Nov 16;13(11):e1006687. (PMID: 29145483) ; Vaccine. 2014 Apr 7;32(17):1946-53. (PMID: 24530932) ; Proc Natl Acad Sci U S A. 2001 May 8;98(10):5752-7. (PMID: 11320211) ; Stat Med. 1997 Feb 28;16(4):385-95. (PMID: 9044528) ; Am J Epidemiol. 2016 Jan 15;183(2):156-66. (PMID: 26646292) ; Nat Commun. 2018 Dec 6;9(1):5208. (PMID: 30523338) ; Trends Immunol. 2022 Aug;43(8):640-656. (PMID: 35842266) ; Chest. 2012 Jul;142(1):63-75. (PMID: 22490872) ; Proc Natl Acad Sci U S A. 2017 May 9;114(19):5023-5028. (PMID: 28438994) ; Nature. 2010 Aug 19;466(7309):973-7. (PMID: 20725040) ; Nat Commun. 2018 Jun 19;9(1):2308. (PMID: 29921861) ; Front Immunol. 2022 Apr 20;13:856906. (PMID: 35514994) ; Front Immunol. 2018 Nov 20;9:2664. (PMID: 30515158) ; Clin Vaccine Immunol. 2011 Dec;18(12):2148-53. (PMID: 21976221) ; J Infect Dis. 2012 Sep 1;206(5):697-705. (PMID: 22732925) ; Nat Rev Immunol. 2009 Apr;9(4):235-45. (PMID: 19319142) ; Am J Respir Crit Care Med. 2018 May 1;197(9):1198-1208. (PMID: 29624071) ; Int J Tuberc Lung Dis. 2004 Apr;8(4):392-402. (PMID: 15141729) ; Cell Syst. 2022 Nov 16;13(11):924-931.e4. (PMID: 36323307) ; J Immunol Methods. 2011 Mar 7;366(1-2):8-19. (PMID: 21192942) ; Clin Infect Dis. 2017 Apr 01;64(7):947-955. (PMID: 28362937) ; mSphere. 2020 May 20;5(3):. (PMID: 32434838) ; EMBO Mol Med. 2016 Nov 2;8(11):1325-1339. (PMID: 27729388) ; Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91. (PMID: 25562578) ; EBioMedicine. 2023 Jul;93:104678. (PMID: 37379655) ; Nat Rev Immunol. 2016 Oct;16(10):626-38. (PMID: 27546235) ; Sci Rep. 2020 May 25;10(1):8629. (PMID: 32451443) ; Nat Immunol. 2021 Dec;22(12):1515-1523. (PMID: 34811542) ; Am J Respir Crit Care Med. 2021 Dec 15;204(12):1463-1472. (PMID: 34520313) ; EMBO Mol Med. 2015 Dec 18;8(2):86-95. (PMID: 26682570) ; J Immunol Methods. 2019 Aug;471:46-56. (PMID: 31132351) ; Cell. 2016 Oct 6;167(2):433-443.e14. (PMID: 27667685) ; Lancet Infect Dis. 2017 Nov;17(11):1190-1199. (PMID: 28827142) ; Lancet Respir Med. 2016 Mar;4(3):213-24. (PMID: 26907218) ; Clin Infect Dis. 2021 Nov 2;73(9):e3486-e3495. (PMID: 32556316) ; Front Immunol. 2021 Jul 05;12:679973. (PMID: 34290702) ; Nat Rev Immunol. 2009 Mar;9(3):185-94. (PMID: 19240757) ; Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14703-8. (PMID: 20668240) ; J Immunol. 2007 Mar 1;178(5):3143-52. (PMID: 17312162) ; Front Immunol. 2021 Sep 22;12:729186. (PMID: 34630406) ; Lancet. 2016 Jun 4;387(10035):2312-2322. (PMID: 27017310) ; Int J Infect Dis. 2020 Mar;92:261-268. (PMID: 32147023) ; PLoS Med. 2019 May 24;16(5):e1002814. (PMID: 31125334) ; Am J Respir Crit Care Med. 2010 Jan 1;181(1):87-93. (PMID: 19797760) ; Nat Med. 2019 Jun;25(6):977-987. (PMID: 31110348) Grant Information: K08 AI167766 United States AI NIAID NIH HHS; 75N93019C00071 United States AI NIAID NIH HHS; OPP1023483 Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation); GC12 grant 37885 Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation); OPP1065330 Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation); K08AI167766 U.S. Department of Health & Human Services \| National Institutes of Health (NIH); GC6-74 grant 37772 Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) Substance Nomenclature: 0 (Antibodies, Bacterial) Entry Date(s): Date Created: 20240424 Date Completed: 20240605 Latest Revision: 20240609 Update Code: 20240609 PubMed Central ID: PMC11153143

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Age and sex influence antibody profiles associated with tuberculosis progression.